The world's first integrated home platform combining AI-powered early detection with breakthrough non-invasive brain therapy that treats and prevents dementia.
Current treatments are expensive, invasive, and ineffective. The global burden is set to triple by 2050, creating an unprecedented healthcare crisis.
People affected by 2050
Annual cost per patient
Clinic visits per year
Treatment efficacy
Revolutionary dual-platform combining non-invasive brain therapy with AI-powered early detection for home use.
Electromagnetic and acoustic stimulation breaks apart protein tangles and stimulates neurogenesis
Smartphone-based cognitive tests detect dementia 5-10 years before symptoms appear
Lightweight device attaches to baseball cap for seamless daily treatment
Real-time symptom tracking with personalized treatment protocols
$1.3 trillion global market growing at 15% annually with clear regulatory pathways and underserved populations.
Total Addressable Market - People over 65 worldwide at risk
Serviceable Addressable Market - North Americans over 65
Serviceable Obtainable Market - Canadians over 65
Our pilot human trials demonstrate significant cognitive improvements with substantial cost savings compared to traditional care.
Cognitive improvement in pilot trials
Annual savings per patient
More patients served than clinical care
Years earlier intervention
We envision a world where Amygo devices are as common as blood pressure monitors in every home, preventing dementia before it starts.
Reduction in global dementia burden by 2044
Lives preserved and enhanced worldwide
Healthcare costs saved globally
Be part of the breakthrough technology that will transform how the world prevents and treats dementia.
Clear regulatory pathway established
Proven efficacy with pilot data
Integrated platform advantage